Research Information System
International Symposium on advances in predictive and personalized medicine, İstanbul, Turkey, 2 - 03 April 2015, pp.21
Backround: Pharmacotherapy is the mainstay of treatment for the psychotic symptoms of mental conditions such as schizophrenia, and bipolar disorder. Genetic variability in drug metabolizing enzymes may influence a patient’s response to commonly prescribed drugs. The aim of this study is to evaluate the CYP1A2, CYP2D6, CYP2C19 polymorphisms of shizophrenic and bipolar patients in the therapeutic response that allow the treatment to be individualized.
Methods: This study was carried out on patients who attended the Cukurova University Psychiatric Unit with a diagnosis of schizophrenia and bipolar disorder involved in our study. Melting curve analysis performed for genotyping CYP1A2 (*1F), CYP2D6 (*3 and *4) and CYP2C19 (*2 and *3) variants.
Results and Conclussion: One hundered and one patients (59 female/ 42 male) involved in our study. Fifty-four of the patients diagnosed with shizophrenia, 47 with bipolar disorder. Ninetheen (37,5 %) of the patients has the CYP2D6 polymorphism 3 (5,9 %) of them found poor metabolizer (PM). There were twenty (39,7 %) patients detected for CYP2C19 polymorphisms, 3 (5,8 %) found PM. The CYP1A2 detected in 28 (51,9 %) of schizophrenia and 22 (46,9 %) of bipolar patients as ultrarapid metabolizers (UM). Genetic determination of patients’ metabolic status is expected to bring clinical benefits by helping to adjust therapeutic doses and reduce adverse reactions. This information may allow the prediction of therapeutic response or treatment to be individualized. Genotyping for the pretreatment prediction of antipsychotic response, although still in its infancy, have obvious implications for the selection and improvement of antipsychotic treatment.